Carpenter Technology Corporation (CRS)

NYQ – Real Time Price. Currency in USD

591.78

-7.46 (-1.24%)

At close: Jun 26, 2026, 4:00 PM EDT

566.01

-25.77 (-4.36%)

After-hours: Jun 26, 2026, 7:54 PM EDT

16.06.2026

Poolbeg's European patent win bolsters partnering case before summer trial data, says Cavendish

Shares in PPoolbeg Pharma PLC (AIM:POLB) rose 3% to 7.8p on Tuesday, taking their gain for the year to date to around 100%, after the drug developer secured a key European patent. The European Patent Office has agreed to grant a patent covering POLB 001, Poolbeg's experimental treatment for preventing cytokine release syndrome (CRS), a dangerous immune reaction triggered by some cancer immunotherapies.

10.06.2026

Carpenter Technology Corporation (CRS) Hits Fresh High: Is There Still Room to Run?

Carpenter (CRS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

10.06.2026

Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon receives US FDA approval for expanded indications of TOFIDENCE, a biosimilar to ACTEMRA, in Cytokine Release Syndrome and Pediatric COVID-19.

08.06.2026

Why Carpenter Technology (CRS) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

04.06.2026

Carpenter Technology (CRS) Is Up 8.03% in One Week: What You Should Know

Does Carpenter Technology (CRS) have what it takes to be a top stock pick for momentum investors? Let's find out.

03.06.2026

Carpenter (CRS) Upgraded to Buy: Here's Why

Carpenter (CRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

03.06.2026

Carpenter Technology Gains on Record Earnings, Profits

Institutional inflows push Carpenter Technology Corporation (CRS) shares up 1,894% since 2005.

Videos

No Data

There is no data to display

Press releases

10.06.2026

Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon receives US FDA approval for expanded indications of TOFIDENCE, a biosimilar to ACTEMRA, in Cytokine Release Syndrome and Pediatric COVID-19.

29.04.2026

Carpenter Technology Reports Third Quarter Fiscal Year 2026 Results

Delivered Another Record Quarterly Operating Income, Up 20 Percent Sequentially Drove Adjusted Operating Margins in Specialty Alloys Operations Segment to Record 35.6 Percent Exceeded Third Quarter Operating Income Guidance for Specialty Alloys Operations Segment Demand Accelerating in Aerospace and Defense End-Use Market Generated $193.5 million of Cash from Operations; $124.8 Million in Adjusted Free Cash Flow Increased Operating Income and Adjusted Free Cash Flow Outlook for Fiscal Year 2026 PHILADELPHIA, April 29, 2026 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) (the “Company”) today announced financial results for the fiscal third quarter ended March 31, 2026. For the quarter, the Company reported operating income of $186.5 million and earnings per diluted share of $2.77.

17.04.2026

Carpenter Technology Declares Quarterly Cash Dividend

PHILADELPHIA, April 17, 2026 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share of common stock, payable June 4, 2026, to shareholders of record on April 28, 2026.

17.02.2026

Carpenter Technology Announces CEO Transition Plan: Brian Malloy to Succeed Tony Thene as Chief Executive Officer on July 1, 2026; Tony Thene to Continue as Executive Chairman

PHILADELPHIA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) (the “Company”) today announced that its Board of Directors has appointed Brian Malloy, currently President & Chief Operating Officer, to serve as Chief Executive Officer effective July 1, 2026. Tony Thene, currently Chairman and CEO, will continue as Executive Chairman of the Board, guiding strategy, maintaining key stakeholder relationships and providing Board leadership.

Carpenter Technology Corporation (CRS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Carpenter Technology Corporation (CRS)

Poolbeg's European patent win bolsters partnering case before summer trial data, says Cavendish

Carpenter Technology Corporation (CRS) Hits Fresh High: Is There Still Room to Run?

Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19

Why Carpenter Technology (CRS) is a Top Growth Stock for the Long-Term

Carpenter Technology (CRS) Is Up 8.03% in One Week: What You Should Know

Carpenter (CRS) Upgraded to Buy: Here's Why

Carpenter Technology Gains on Record Earnings, Profits

Videos

No Data

Press releases

Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19

Carpenter Technology Reports Third Quarter Fiscal Year 2026 Results

Carpenter Technology Declares Quarterly Cash Dividend

Carpenter Technology Announces CEO Transition Plan: Brian Malloy to Succeed Tony Thene as Chief Executive Officer on July 1, 2026; Tony Thene to Continue as Executive Chairman

Poolbeg's European patent win bolsters partnering case before summer trial data, says Cavendish

Carpenter Technology Corporation (CRS) Hits Fresh High: Is There Still Room to Run?

Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19

Why Carpenter Technology (CRS) is a Top Growth Stock for the Long-Term

Carpenter Technology (CRS) Is Up 8.03% in One Week: What You Should Know

Carpenter (CRS) Upgraded to Buy: Here's Why

Carpenter Technology Gains on Record Earnings, Profits

Videos

No Data

Press releases

Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19

Carpenter Technology Reports Third Quarter Fiscal Year 2026 Results

Carpenter Technology Declares Quarterly Cash Dividend

Carpenter Technology Announces CEO Transition Plan: Brian Malloy to Succeed Tony Thene as Chief Executive Officer on July 1, 2026; Tony Thene to Continue as Executive Chairman

Search stocks

Carpenter Technology Corporation (CRS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Carpenter Technology Corporation (CRS)

Poolbeg's European patent win bolsters partnering case before summer trial data, says Cavendish

Carpenter Technology Corporation (CRS) Hits Fresh High: Is There Still Room to Run?

Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19

Why Carpenter Technology (CRS) is a Top Growth Stock for the Long-Term

Carpenter Technology (CRS) Is Up 8.03% in One Week: What You Should Know

Carpenter (CRS) Upgraded to Buy: Here's Why

Carpenter Technology Gains on Record Earnings, Profits

Videos

No Data

Press releases

Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19

Carpenter Technology Reports Third Quarter Fiscal Year 2026 Results

Carpenter Technology Declares Quarterly Cash Dividend

Carpenter Technology Announces CEO Transition Plan: Brian Malloy to Succeed Tony Thene as Chief Executive Officer on July 1, 2026; Tony Thene to Continue as Executive Chairman

Poolbeg's European patent win bolsters partnering case before summer trial data, says Cavendish

Carpenter Technology Corporation (CRS) Hits Fresh High: Is There Still Room to Run?

Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19

Why Carpenter Technology (CRS) is a Top Growth Stock for the Long-Term

Carpenter Technology (CRS) Is Up 8.03% in One Week: What You Should Know

Carpenter (CRS) Upgraded to Buy: Here's Why

Carpenter Technology Gains on Record Earnings, Profits

Videos

No Data

Press releases

Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19

Carpenter Technology Reports Third Quarter Fiscal Year 2026 Results

Carpenter Technology Declares Quarterly Cash Dividend

Carpenter Technology Announces CEO Transition Plan: Brian Malloy to Succeed Tony Thene as Chief Executive Officer on July 1, 2026; Tony Thene to Continue as Executive Chairman